U.S. Stem Cell, Inc. (USRM)
| Market Cap | 14.25M |
| Revenue (ttm) | 4.43M |
| Net Income (ttm) | -3.60M |
| Shares Out | 396.64M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $0.0325 |
| Previous Close | $0.0350 |
| Change ($) | -0.0030 |
| Change (%) | -7.14% |
| Day's Open | 0.0398 |
| Day's Range | 0.0320 - 0.0401 |
| Day's Volume | 4,817,612 |
| 52-Week Range | 0.003 - 0.048 |
News
There are no news available yet.
About USRM
U.S. Stem Cell, a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient... [Read more...]
| Industry Biotechnology | IPO Date Feb 15, 2008 |
| CEO Mike Tomas | Employees 10 |
| Stock Exchange OTCMKTS | Ticker Symbol USRM |
Financial Performance
In 2018, U.S. Stem Cell's revenue was $6.70 million, an increase of 21.38% compared to the previous year's $5.52 million. Losses were -$2.16 million, -37.95% less than in 2017.